Politicizing Science
Biopharmaceutical Report I Issue12_December 2016 POLITICIZING SCIENCE BY STEVE USDIN, WASHINGTON EDITOR While the FDA reform provisions...
Politicizing Science
NY-ESO-1 therapy renewed enthusiasm underscored by new checkpoint inhibitors
Democratizing Antibodies
FDA Review Policies for PD-1/PD-L1 Inhibitors Spark Expert Debate
PCSK9 Inhibitor Competition: Amgen, Scanofi, and Regeneron Show Equally Decent CVOT Outlooks
South Korea Trials Drive Further Opportunities for Global Pharma and CROs
Changing the Channel
Early CAR-T multiple myeloma data promising, though efficacy, safety remain unclear
Samsung RA biosimilar EU uptake tied to perceived cost despite physician concerns
Controlling Drug Prices